ARGATROBAN IN 0.9% SODIUM CHLORIDE Drug Patent Profile

Which patents cover Argatroban In 0.9% Sodium Chloride, and what generic alternatives are available?

Argatroban In 0.9% Sodium Chloride is a drug marketed by Teva Pharms Usa and is included in one NDA.

The generic ingredient in ARGATROBAN IN 0.9% SODIUM CHLORIDE is argatroban. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the argatroban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Argatroban In 0.9% Sodium Chloride

A generic version of ARGATROBAN IN 0.9% SODIUM CHLORIDE was approved as argatroban by HIKMA PHARM CO LTD on January 5^th, 2012.

Summary for ARGATROBAN IN 0.9% SODIUM CHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	35
DailyMed Link:	ARGATROBAN IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of Vienna	PHASE4
Veralox Therapeutics	Phase 2
Veralox Therapeutics	Phase 1

See all ARGATROBAN IN 0.9% SODIUM CHLORIDE clinical trials

US Patents and Regulatory Information for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ARGATROBAN IN 0.9% SODIUM CHLORIDE	argatroban	INJECTABLE;INTRAVENOUS	206769-001	Dec 15, 2014		DISCN	No	No

Argatroban in 0.9% Sodium Chloride: Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 13, 2026

Argatroban in 0.9% sodium chloride is a mature, generic hospital injectable used mainly for heparin-induced thrombocytopenia (HIT) and, in limited circumstances, percutaneous coronary intervention. Its commercial profile is defined by low clinical volume, high treatment criticality, institutional purchasing, and limited supplier depth. The product has no meaningful biosimilar risk, no material active-ingredient patent barrier, and limited public revenue disclosure because manufacturers generally report it within broader injectable portfolios.

What is argatroban in 0.9% sodium chloride?

Argatroban is a small-molecule direct thrombin inhibitor supplied as a ready-to-use intravenous solution diluted in 0.9% sodium chloride. The formulation avoids bedside dilution and reduces compounding steps in hospital pharmacies.

Attribute	Profile
Active ingredient	Argatroban
Dosage form	Intravenous injection
Common concentration	1 mg/mL
Typical container	Single-dose flexible infusion bags
Primary indication	Anticoagulation in adults with HIT
Secondary indication	Anticoagulation during PCI in patients with HIT or at risk of HIT
FDA pathway	Generic ANDA products and associated labeling
Reference product	Acova, formerly marketed by GlaxoSmithKline
Therapeutic class	Direct thrombin inhibitor
Main customers	Hospitals, health systems, group purchasing organizations and specialty distributors
Biosimilar exposure	None

The FDA label requires dose adjustment and close monitoring with activated partial thromboplastin time. Argatroban is hepatically metabolized, making hepatic impairment a central prescribing and procurement consideration. [1]

What is the FDA regulatory status of argatroban premixed in saline?

Argatroban in 0.9% sodium chloride is an FDA-approved generic hospital product. The product is generally supplied under abbreviated new drug applications rather than a currently marketed branded new drug application.

The regulatory value of the premixed presentation is operational rather than clinical. The product offers:

• Reduced pharmacy preparation time
• Lower risk of dilution or calculation errors
• Simplified emergency use in intensive-care and procedural settings
• Standardized concentration across hospital formularies
• Lower need for sterile compounding capacity

The product competes primarily on supply reliability, contract price, container configuration and distribution reach. It does not generally compete through physician-directed brand promotion.

What is the Orange Book status of argatroban in 0.9% sodium chloride?

The product is not protected by a commercially significant period of new-drug exclusivity. Argatroban's active ingredient and core clinical use are long established, and generic products entered after the expiration of the original Acova-related intellectual-property and regulatory barriers.

An Orange Book assessment should distinguish between:

1. The original branded NDA and its historical patent listings.
2. Generic ANDA products.
3. Container, formulation or manufacturing patents that may exist outside the principal Orange Book barrier.

For hospital procurement, the relevant conclusion is that current competition is not materially constrained by a listed active-ingredient patent. FDA Orange Book listings should be checked by specific application number and product sponsor because listings can vary by dosage form and applicant. [2]

When does argatroban lose exclusivity?

Argatroban has already lost meaningful market exclusivity in the United States.

The original Acova product was approved for HIT-related anticoagulation in 2000. The core compound, clinical use and conventional injectable presentation are now mature generic assets. Any original composition-of-matter or basic-use patent protection would have expired years ago under the standard U.S. patent term framework.

Exclusivity category	Current commercial significance
Active-ingredient patent	Expired or no longer commercially blocking
Original branded product exclusivity	Expired
Orphan-drug exclusivity	No current blocking period for generic premix products
Pediatric exclusivity	No material current barrier identified
Generic approval pathway	Available
Biosimilar exclusivity	Not applicable

The remaining defensibility is primarily execution-based: manufacturing approvals, sterile-fill capability, validated bag systems, supply contracts, inventory and regulatory compliance.

What patents protect argatroban in 0.9% sodium chloride?

The core drug is not meaningfully protected by a live patent estate comparable to newer specialty pharmaceuticals. Any residual patent risk would be more likely to arise from a specific presentation, container, stabilizer system, manufacturing process or delivery configuration rather than from argatroban itself.

Are formulation patents important for argatroban premix products?

Formulation patents have limited strategic value in this market unless they materially improve stability, container compatibility, shelf life or manufacturing economics.

A premixed argatroban product can create technical barriers around:

• Long-term chemical stability in saline
• Adsorption to container materials
• Extractables and leachables
• Sterility assurance
• Terminal sterilization or aseptic processing
• Compatibility with infusion equipment
• Shelf-life validation
• Bag port and closure design

These barriers can delay entry for a particular manufacturer, but they do not normally prevent substitution across the market. Hospitals can purchase another FDA-approved argatroban product if it carries an equivalent concentration and acceptable packaging.

Are method-of-use patents relevant?

Method-of-use patents have limited commercial leverage because the principal HIT indication is established and generic labels generally follow the reference product. Any historical use patents would not ordinarily block an approved generic with the same indication after expiration.

The practical risk is regulatory rather than patent-based. A manufacturer may need to address labeling differences, therapeutic equivalence, pharmacokinetic information and use in hepatic impairment. These issues affect approval and adoption but do not create durable exclusivity comparable to a novel indication patent.

How many manufacturers compete in the argatroban premix market?

The U.S. market has historically included generic injectable suppliers and specialty hospital-drug manufacturers. Market participation can change rapidly because manufacturers may discontinue low-volume products, transfer applications or prioritize higher-margin injectables.

Potential supplier categories include:

• Large generic injectable companies
• Hospital-focused manufacturers
• Contract manufacturing organizations
• Specialty anticoagulant suppliers
• Distributors selling private-label or relabeled inventory

The market is less competitive than the number of approved applications might suggest. A product can have several approved suppliers but only a small number of active manufacturers with dependable inventory. The relevant competitive measure is therefore available commercial supply, not merely the number of FDA-approved applications.

What are the main market dynamics for argatroban in saline?

Hospital demand is clinically necessary but episodic

Argatroban demand is concentrated in patients with suspected or confirmed HIT, a relatively uncommon but high-risk condition. Utilization is episodic and tied to intensive-care admissions, cardiac procedures, extracorporeal circuits and complex inpatient cases.

Demand has several stable characteristics:

• Low unit volume relative to routine anticoagulants
• High willingness to pay during a shortage
• Rapid use once HIT is suspected
• Limited substitution when clinicians require a direct thrombin inhibitor
• Concentrated purchasing by hospitals and health systems

Because treatment is often urgent, hospitals value availability more than small price differences.

Premixed bags compete against vial presentations

The major commercial distinction is convenience. Vial presentations require preparation, while premixed bags can be connected directly to an infusion system after verification.

Factor	Premixed saline bag	Concentrated vial
Pharmacy preparation	Minimal	Required
Medication-error risk	Lower operational risk	Higher preparation burden
Inventory footprint	Larger physical volume	Smaller
Unit economics	Often higher per treatment unit	Potentially lower
Emergency deployment	Faster	Requires dilution and verification
Hospital preference	Strong in high-acuity settings	Useful where cost or inventory dominates

Premixed products can command a price premium when they reduce pharmacy labor and support emergency readiness. That premium is limited by generic contracting and hospital budget controls.

Shortages have an outsized impact

Argatroban is vulnerable to supply disruptions because the market is small and production is technically demanding. A disruption at one sterile-injectable facility can materially affect national availability.

Shortage drivers can include:

• Manufacturing deviations
• Facility remediation
• Raw-material shortages
• Container or closure constraints
• Product discontinuation
• Shipping interruptions
• Low forecast accuracy
• Allocation by manufacturers or distributors

When supply tightens, hospitals may conserve premixed bags, switch to vials, use alternative direct thrombin inhibitors such as bivalirudin, or implement pharmacy-controlled dosing protocols.

What is the financial trajectory for argatroban in 0.9% sodium chloride?

No major manufacturer generally reports standalone revenue for argatroban in 0.9% sodium chloride. Financial analysis therefore relies on market structure, product availability, pricing and hospital procurement behavior rather than audited product-level sales.

The product's financial trajectory is likely characterized by:

1. Mature demand with limited volume growth.
2. Price pressure from generic competition.
3. Periodic price expansion during shortages.
4. Higher value for premixed presentations than for undifferentiated active ingredient.
5. Revenue volatility tied to supplier exits and hospital inventory cycles.

Revenue outlook

Period	Expected commercial pattern
Early generic era	Rapid share capture from branded Acova and price erosion
Mature generic period	Stable but low-volume hospital demand
Shortage periods	Temporary price increases and supplier share gains
Normalized supply	Contract-price compression and revenue normalization
Long term	Flat unit demand with episodic supply-driven revenue changes

A manufacturer with a dependable premix supply can generate attractive contribution margins despite modest sales because the product is operationally important and competes in a less crowded niche than oral generics. The counterweight is low absolute revenue, limited prescribing growth and the cost of maintaining sterile manufacturing compliance.

What generic entry risks exist for argatroban?

The primary generic-entry risk is not a new entrant capturing a large chronic market. It is incremental price and volume pressure from an additional approved supplier.

Commercial risks

• Hospital systems may consolidate purchases through national contracts.
• Group purchasing organizations can force price reductions.
• Vial products can substitute for premixed bags during budget pressure.
• Bivalirudin can capture selected procedural demand.
• Hospitals can reduce safety stock when supply improves.
• Manufacturers may launch only when market pricing supports sterile production.

Regulatory risks

Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence or rely on applicable FDA standards for injectable products. Labeling must address dosing, monitoring, hepatic impairment, contraindications and preparation requirements. [1]

The principal regulatory risk for an incumbent is supply-performance failure. A manufacturing warning letter, recall or repeated back order can cause hospitals to qualify competitors quickly.

Which companies are challenging argatroban's market position?

Competition comes from both argatroban suppliers and clinically substitutable anticoagulants.

Direct competitors

Direct competitors are manufacturers of generic argatroban injection, including suppliers of:

• Premixed argatroban in 0.9% sodium chloride
• Concentrated argatroban vials
• Alternative bag sizes and container systems

The commercial identity of these products can change as applications are transferred or manufacturers discontinue low-volume injectables.

Therapeutic competitors

Bivalirudin is the most relevant alternative direct thrombin inhibitor in procedural anticoagulation, particularly in PCI and selected cardiac settings. Fondaparinux and danaparoid may be considered in some HIT management contexts depending on jurisdiction and clinical circumstances, but they do not provide a direct one-for-one replacement in every inpatient scenario. [3]

Unfractionated heparin and low-molecular-weight heparins are not direct substitutes when HIT is suspected because of their relationship to the underlying immune-mediated adverse event.

What patent litigation and Paragraph IV risk affect argatroban?

Argatroban does not present a major current Paragraph IV litigation profile comparable to recently launched specialty drugs. Its core patents and branded exclusivities are historical. Generic litigation risk is more likely to involve:

• Product-specific formulation patents
• Container or closure claims
• Manufacturing-process patents
• Paragraph IV certification disputes involving a particular ANDA
• Contract and supply disputes
• Product liability or shortage-related claims

There is no material biosimilar litigation pathway because argatroban is a chemically synthesized small molecule, not a biologic. Any current patent assessment must be performed at the ANDA and sponsor level, since an individual applicant can face a formulation or process claim even when the broader molecule is off patent.

How strong is the patent estate for argatroban?

The patent estate is weak as a barrier to generic competition and moderate only as a technical barrier to reliable sterile presentation.

Patent or barrier type	Strength
Composition of matter	Very weak or expired
Core HIT method of use	Very weak or expired
Premixed saline formulation	Potentially narrow
Container and packaging	Potentially narrow
Manufacturing process	Potentially relevant but avoidable
Regulatory and quality systems	Stronger practical barrier than patents
Distribution and hospital contracts	Important commercial barrier
Biosimilar exclusivity	Not applicable

The strongest protection for a supplier is operational. A manufacturer with validated stability data, national distribution, shortage-ready inventory and hospital contracts can defend share without a substantial patent estate.

What licensing deals affect argatroban in 0.9% sodium chloride?

The historical product lineage traces to argatroban development by Mitsubishi Tanabe Pharma and U.S. commercialization of Acova by GlaxoSmithKline. Current premixed generic products are generally commercialized through manufacturer-owned or contracted generic supply structures.

No widely disclosed current licensing arrangement appears to define the U.S. premixed argatroban market. Any relevant deal is more likely to involve:

• ANDA ownership transfer
• Contract manufacturing
• Private-label supply
• Distributor agreements
• Hospital or group-purchasing contracts

These arrangements can affect market share without creating public patent exclusivity.

What is the geographic coverage of argatroban premix products?

The United States is the most commercially structured market for this specific presentation because of FDA-approved hospital injectable products, Orange Book-linked procurement and GPO contracting.

Outside the United States, availability varies by:

• National authorization requirements
• Hospital formulary policy
• Local use of alternative anticoagulants
• Reimbursement systems
• Availability of premixed versus concentrate presentations
• Regional sterile-injectable manufacturing

The product's international revenue potential is limited by its narrow indication and the fact that many countries manage HIT through different dosing protocols or alternative agents.

What generic launch scenarios are most likely?

Base case

Stable low-volume demand, periodic contract repricing and modest supplier turnover. Premixed products retain a convenience premium, but overall market growth remains limited.

Upside case

A competitor exits or experiences a prolonged shortage. Remaining suppliers gain volume, improve pricing and increase hospital adoption of premixed bags.

Downside case

Several suppliers maintain inventory simultaneously, hospitals switch to lower-cost vial presentations and GPO contracts compress net pricing.

Strategic case

A manufacturer uses argatroban as part of a broader hospital injectable portfolio. The product may be commercially valuable because it strengthens account access and improves portfolio completeness, even if standalone revenue is modest.

Key Takeaways

• Argatroban in 0.9% sodium chloride is a mature generic hospital injectable.
• The core molecule and established HIT use do not provide meaningful current patent protection.
• No biosimilar risk exists because argatroban is a small molecule.
• Premixed bags have a practical advantage over vials through lower preparation burden and faster deployment.
• Revenue is not typically disclosed separately by public manufacturers.
• Financial performance depends more on supply reliability, shortages and hospital contracts than on prescription growth.
• The market has limited volume expansion but can produce temporary pricing power during sterile-injectable shortages.
• The strongest barriers are manufacturing quality, validated stability, distribution and procurement relationships.
• Bivalirudin is the principal therapeutic competitor in selected procedural settings.
• Generic-entry risk is primarily incremental price erosion and supplier competition, not a large-scale loss of exclusivity event.

FAQs

Is argatroban in 0.9% sodium chloride a branded drug?

No. It is generally marketed as a generic FDA-approved injectable product, although specific manufacturers may use distinct trade names, labels or private-label arrangements.

Can argatroban premix be substituted automatically at the hospital level?

Substitution depends on institutional formulary rules, concentration, container size, FDA equivalence status, purchasing policy and pharmacy procedures. Premixed bags and vials may not be operationally interchangeable without preparation changes.

Is argatroban affected by the Inflation Reduction Act drug-price negotiations?

The product is unlikely to be a principal target because it is an old generic injectable with low standalone commercial revenue. Medicare negotiation focuses on selected high-spend branded drugs and biologics rather than mature generic hospital products.

Why can a generic argatroban product remain expensive after patent expiration?

Sterile injectable manufacturing, quality compliance, limited scale, shortage exposure and hospital urgency can preserve pricing above the level expected for ordinary oral generics.

Does argatroban compete with heparin in patients with HIT?

It is used specifically when heparin must be stopped or avoided because of suspected or confirmed HIT. Heparin is therefore not a direct substitute in that clinical setting, although treatment protocols may use other non-heparin anticoagulants.

References

1. U.S. Food and Drug Administration. (n.d.). Argatroban injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Cuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Selleng, K., Warkentin, T. E., Wexels, F., Mustafa, R. A., Morgan, R. L., & Santesso, N. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia. Blood Advances, 2(22), 3360-3392. https://doi.org/10.1182/bloodadvances.2018024489

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. GlaxoSmithKline. (2000). Acova (argatroban) injection prescribing information. U.S. Food and Drug Administration.